Article Details
Retrieved on: 2022-09-11 06:34:34
Tags for this article:
Click the tags to see associated articles and topics
Excerpt
Updated results from the pivotal ADAURA Phase III trial showed that AstraZeneca's Tagrisso (osimertinib) demonstrated a sustained, clinically.
Article found on: www.miragenews.com
This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here